5 results about "Tissue concentrations" patented technology

This invention provides a method for assessing the risk of hemorrhagic transformation based on a two-compartment model, comprising: acquiring CT perfusion image sequences related to the risk of hemorrhagic transformation; extracting arterial input functions and tissue concentration-time curves from the CT perfusion image sequences; extracting spatiotemporal features from the CT perfusion image sequences using a Transformer network; inputting the spatiotemporal features into a physical information neural network and processing them through a two-compartment model to obtain preliminary parameter estimates and parameter constraint terms; determining a joint loss function based on the preliminary parameter estimates and parameter constraint terms, and using the arterial input function and tissue concentration-time curves, wherein the joint loss function includes a data fitting loss term for fitting the observed data and a physical constraint loss term for constraining the physical consistency of the two-compartment model; and assessing the risk of hemorrhagic transformation based on the joint loss function. The parameters estimated by this invention have clear physical meaning and strictly conform to the physical model, making them easy for clinicians to understand and apply, and improving the reliability of the results.

The present application provides a kind of potassium channel regulator, its preparation method, pharmaceutical composition and application. Specifically provided are compounds as shown in formula V or pharmaceutically acceptable salts thereof. The potassium channel regulator compound of the present application has one or more of the following effect advantages: (1) novel structure; (2) good KCNQ2 / 3 channel opening activity; (3) weak KCNQ4, KCNQ5 opening activity, high KCNQ2 / 3 selectivity; (4) good in vivo efficacy, good protection effect on seizures; (5) low neuro-motor toxicity; (6) high brain-blood ratio; (7) high plasma, brain tissue concentration.

The present invention provides a potassium channel modulator and a preparation method therefor, a pharmaceutical composition and a use. Specifically provided is a compound represented by formula V or a pharmaceutically acceptable salt thereof. The potassium channel modulator compound of the present invention has one or more of the following advantages: (1) a novel structure; (2) good KCNQ2 / 3 channel opening activity; (3) weak opening activity for KCNQ4 and KCNQ5 and high selectivity for KCNQ2 / 3; (4) good in vivo efficacy and effective protection against epileptic seizures; (5) low neuro-motor toxicity; (6) a high brain-to-blood ratio; and (7) high concentrations in plasma and brain tissue.

This invention provides a dosage regimen for the treatment of BK or JC polyomavirus infection in human subjects. [Solution] The administration regimen includes the steps of (a) parenterally administering a dose of an antibody or antigen-binding fragment that specifically binds to the VP1 protein of the polyomavirus to the subject; (b) measuring the serum or tissue concentration of the antibody or antigen-binding fragment in the subject; and (c) measuring the serum or tissue trough concentration (C trough The administration regimen includes the step of administering a further dose of the antibody or its antigen-binding fragment before the concentration drops to less than approximately 3-860 μg / mL, wherein the concentration of the antibody or its antigen-binding fragment in the serum or tissue during the treatment is reduced to the C trough Maintain a higher position.

A method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to which a therapeutic antibody has been administered is reported herein, wherein the interference of residual blood in a tissue sample from the experimental animal for determining the concentration of the therapeutic antibody in said tissue is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the formula: C tmAb,组织,det. = obtained by determining the concentration of the therapeutic antibody in a tissue sample of the experimental animal, C tmAb,血浆,det. = obtained by determining the concentration of the therapeutic antibody in a blood sample of the experimental animal directly before taking the tissue sample, C refmAb,组织,det. = obtained by determining the concentration of an inert reference antibody in a tissue sample of the experimental animal, C refmAb,血浆,det. = obtained by determining the concentration of an inert reference antibody in a blood sample of the experimental animal directly before taking the tissue sample, C 组织,样品 = obtained by determining the tissue concentration in the tissue sample, wherein the inert reference antibody does not penetrate into said tissue, wherein the inert reference antibody is administered 2 to 10 minutes before obtaining the tissue and blood samples.